铂类化疗通过细胞衰老使卵巢癌微环境发生炎症。
Platinum-based chemotherapy inflames the ovarian carcinoma microenvironment through cellular senescence.
作者信息
Álvarez-Abril Beatriz, García-Martínez Elena, Galluzzi Lorenzo
机构信息
Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
Department of Hematology and Oncology, Morales Meseguer University Hospital, Murcia, Spain.
出版信息
Oncoimmunology. 2022 Mar 17;11(1):2052411. doi: 10.1080/2162402X.2022.2052411. eCollection 2022.
Abstract
Epithelial ovarian carcinoma (EOC) is virtually insensitive to immune checkpoint inhibitors (ICIs). Recent findings from an innovative mouse model of EOC demonstrate that senescence induction underlies the increased sensitivity of homologous recombination-defective EOCs to platinum-based chemotherapy as it initiates tumor infiltration by immune effector cells coupled to restored sensitivity to ICIs.
摘要
上皮性卵巢癌（EOC）对免疫检查点抑制剂（ICI）几乎不敏感。最近来自一种创新的EOC小鼠模型的研究结果表明，衰老诱导是同源重组缺陷型EOC对铂类化疗敏感性增加的基础，因为它启动了免疫效应细胞的肿瘤浸润，并恢复了对ICI的敏感性。
相似文献
1
Platinum-based chemotherapy inflames the ovarian carcinoma microenvironment through cellular senescence.铂类化疗通过细胞衰老使卵巢癌微环境发生炎症。
Oncoimmunology. 2022 Mar 17;11(1):2052411. doi: 10.1080/2162402X.2022.2052411. eCollection 2022.
2
NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer.NAMPT 抑制抑制卵巢癌中与治疗诱导衰老相关的癌症干细胞样细胞。
Cancer Res. 2020 Feb 15;80(4):890-900. doi: 10.1158/0008-5472.CAN-19-2830. Epub 2019 Dec 19.
3
Ovarian Cancer-Insights into Platinum Resistance and Overcoming It.卵巢癌—铂耐药机制及克服策略
Medicina (Kaunas). 2023 Mar 10;59(3):544. doi: 10.3390/medicina59030544.
4
Prognostic impact of human leukocyte antigen class I expression and association of platinum resistance with immunologic profiles in epithelial ovarian cancer.人类白细胞抗原 I 类表达的预后影响及上皮性卵巢癌中铂耐药与免疫谱的关系。
Cancer Immunol Res. 2014 Dec;2(12):1220-9. doi: 10.1158/2326-6066.CIR-14-0101. Epub 2014 Oct 16.
5
A Predictive Model for Initial Platinum-Based Chemotherapy Efficacy in Patients with Postoperative Epithelial Ovarian Cancer Using Tissue-Derived Small Extracellular Vesicles.基于组织来源的小细胞外囊泡预测上皮性卵巢癌术后患者初始铂类化疗疗效的模型。
J Extracell Vesicles. 2024 Aug;13(8):e12486. doi: 10.1002/jev2.12486.
6
Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer.衰老诱导决定了卵巢癌临床前模型中对化疗和免疫治疗的反应。
Proc Natl Acad Sci U S A. 2022 Feb 1;119(5). doi: 10.1073/pnas.2117754119.
7
Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?携带BRCA1和BRCA2基因突变的卵巢癌患者的化疗：相同还是不同？
Am Soc Clin Oncol Educ Book. 2015:114-21. doi: 10.14694/EdBook_AM.2015.35.114.
8
A novel CSN5/CRT O-GlcNAc/ER stress regulatory axis in platinum resistance of epithelial ovarian cancer.上皮性卵巢癌中新型 CSN5/CRT O-GlcNAc/内质网应激调节轴与铂耐药相关。
Int J Biol Sci. 2024 Jan 27;20(4):1279-1296. doi: 10.7150/ijbs.89700. eCollection 2024.
9
CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation.CDK6 通过 FOXO3 调控保护卵巢上皮性癌细胞免于铂类诱导的死亡。
EMBO Mol Med. 2017 Oct;9(10):1415-1433. doi: 10.15252/emmm.201607012.
10
Whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy.铂类耐药的卵巢上皮癌的全外显子组测序。
Life Sci Alliance. 2022 Oct 13;5(12):e202201551. doi: 10.26508/lsa.202201551.
引用本文的文献
1
Correlation of senescence-related gene FEN1 on neuroblastoma progression and cisplatin chemotherapy sensitivity.衰老相关基因FEN1与神经母细胞瘤进展及顺铂化疗敏感性的相关性
Oncol Res. 2025 Jun 26;33(7):1695-1708. doi: 10.32604/or.2025.060021. eCollection 2025.
2
A lncRNA-mediated metabolic rewiring of cell senescence.一种长链非编码RNA介导的细胞衰老代谢重编程。
Cell Rep. 2025 Jun 24;44(6):115747. doi: 10.1016/j.celrep.2025.115747. Epub 2025 May 21.
3
Senescence-related genes analysis in breast cancer reveals the immune microenvironment and implications for immunotherapy.乳腺癌相关衰老基因分析揭示免疫微环境及其对免疫治疗的影响。
Aging (Albany NY). 2024 Feb 14;16(4):3531-3553. doi: 10.18632/aging.205544.
本文引用的文献
1
Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents.化疗和靶向抗癌药物对卵巢癌的免疫控制。
Trends Cancer. 2022 May;8(5):426-444. doi: 10.1016/j.trecan.2022.01.010. Epub 2022 Feb 16.
2
Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer.衰老诱导决定了卵巢癌临床前模型中对化疗和免疫治疗的反应。
Proc Natl Acad Sci U S A. 2022 Feb 1;119(5). doi: 10.1073/pnas.2117754119.
3
Modeling High-Grade Serous Ovarian Carcinoma Using a Combination of Fallopian Tube Electroporation and CRISPR-Cas9-Mediated Genome Editing.利用输卵管电穿孔和 CRISPR-Cas9 介导的基因组编辑联合方法建立高级别浆液性卵巢癌模型。
Cancer Res. 2021 Oct 15;81(20):5147-5160. doi: 10.1158/0008-5472.CAN-20-1518. Epub 2021 Jul 23.
4
Senescence Inflames the Pancreatic Tumor Microenvironment.衰老引发胰腺肿瘤微环境炎症。
Cell Rep Med. 2020 May 19;1(2):100020. doi: 10.1016/j.xcrm.2020.100020.
5
Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy.线粒体 DNA 驱动放疗的远隔效应，自噬会抑制这种远隔效应。
Nat Immunol. 2020 Oct;21(10):1160-1171. doi: 10.1038/s41590-020-0751-0. Epub 2020 Aug 3.
6
Cellular Senescence: Defining a Path Forward.细胞衰老：定义前进的道路。
Cell. 2019 Oct 31;179(4):813-827. doi: 10.1016/j.cell.2019.10.005.
7
High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints.高级别浆液性卵巢癌：基础科学、临床和治疗观点。
Int J Mol Sci. 2019 Feb 22;20(4):952. doi: 10.3390/ijms20040952.
8
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.PARP 抑制剂在 BRCA1 缺陷型卵巢癌中引发 STING 依赖性抗肿瘤免疫。
Cell Rep. 2018 Dec 11;25(11):2972-2980.e5. doi: 10.1016/j.celrep.2018.11.054.
9
The hallmarks of successful anticancer immunotherapy.成功的抗癌免疫疗法的特征。
Sci Transl Med. 2018 Sep 19;10(459). doi: 10.1126/scitranslmed.aat7807.
10
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.BRCA1/2基因突变状态与高级别浆液性卵巢癌新抗原负荷、肿瘤浸润淋巴细胞数量及PD-1/PD-L1表达的相关性及预后意义
Oncotarget. 2016 Mar 22;7(12):13587-98. doi: 10.18632/oncotarget.7277.
Zotero 插件